Topics

FDA Approves Clinuvel’s Scenesse, the First Treatment for a Rare Genetic Metabolic Disorder that Causes Light Intolerance

14:26 EDT 9 Oct 2019 | Speciality Pharma Journal

MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) — The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute intolerance to light. SCENESSE® (afamelanotide 16mg), the first drug developed by Australian biopharmaceutical company CLINUVEL, has been approved to “increase pain …

Original Article: FDA Approves Clinuvel’s Scenesse, the First Treatment for a Rare Genetic Metabolic Disorder that Causes Light Intolerance

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Clinuvel’s Scenesse, the First Treatment for a Rare Genetic Metabolic Disorder that Causes Light Intolerance"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...